Laboratory

The BioFire-Respiratory Panel 2.1 is a comprehensive, multiplex PCR-based diagnostic test that simultaneously detects and identifies 22 common respiratory pathogens—including SARS-CoV-2, influenza A/B, RSV, rhinovirus/enterovirus, adenovirus and several bacteria—from a single nasopharyngeal swab sample. The panel offers rapid, accurate and actionable insights for clinicians to differentiate between viral and bacterial infections.

The BioFire Blood Culture Identification (BCID) panel is a rapid molecular test used to identify the causative agent of bloodstream infections (BSIs) in patients with positive blood cultures. It detects multiple pathogens and antimicrobial resistance genes in a single test, aiding in the timely management of sepsis and other BSI-related conditions. The panel is typically used on the BioFire FilmArray system.
Here’s a more detailed breakdown:
Purpose:
Rapid Identification:
The BCID panel helps quickly identify the specific bacteria, fungi, or other microorganisms responsible for a bloodstream infection.
Antimicrobial Resistance Detection:
It also detects genetic markers associated with antimicrobial resistance, allowing for better-targeted antibiotic therapy.
Improved Sepsis Management:
Rapid identification and resistance detection can lead to quicker adjustment of broad-spectrum antibiotics to more specific regimens, potentially reducing antibiotic use and hospital stay.
How it Works:
Multiplex PCR: The panel uses a multiplex PCR (polymerase chain reaction) technology to detect multiple targets simultaneously.
FilmArray System: It is designed for use with the BioFire FilmArray system.
Sample Preparation: A positive blood culture sample is processed, and the DNA is amplified and analyzed within the FilmArray system.
Benefits:
Faster Results:
The test provides results in about an hour from a positive blood culture, compared to days for traditional culture-based methods.